Polaryx Therapeutics, Inc. Common Stock beat EPS estimates 100% of the time across 1 reported quarters (1 beats, 0 misses), averaging +40.0% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.05 | $-0.03 | +40.0% | Beat | |
| Q1 FY26 | not reported | $-0.05 | not reported | not reported |
Back to PLYX overview · PLYX holders · PLYX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.